Oncoinvent

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin at ESGO 2026

9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose 17 February 2026 -- Oslo, Norway -- Oncoinvent, a biotech developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced that it will...
Gullhaugveien 7 0484 Oslo Norway

+47 22 18 33 05